

Supplementary material

Patel A, Masiak A, Joshi S, et al. Influence of smoking on disease activity and prognosis of antineutrophil cytoplasmic antibody–associated vasculitis: a retrospective cohort study. *Pol Arch Intern Med.* 2023; 133: 16478. doi:10.20452/pamw.16478

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Supplementary Table S1: Comparison between never and ever smokers dichotomized based on Gender.

	Males (n=121)			Females (n=102)		
	Ever Smokers (n=76)	Never Smokers (n=45)	P-value	Never Smokers (n=71)	Ever Smokers (n=31)	P-value
Age at diagnosis, years, mean (SD)	54.59 (13.89)	52.09 (16.40)	0.37	51.3 (16.75)	56.48 (16.97)	0.16
Clinical Manifestations, n (%)						
Renal Involvement:						
Involvement at diagnosis	62 (82)	33 (73)	0.25	37 (52)	14 (45)	0.67
Kidney failure at diagnosis	48 (63)	24 (53)	0.44	29 (41)	11 (36)	0.66
Proteinuria	53 (70)	30 (67)	0.69	32 (45)	12 (39)	0.67
Hematuria	59 (78)	34 (76)	0.82	35 (49)	14 (45)	0.83
Need for RRT at diagnosis	27 (36)	8 (18)	0.04	9 (13)	7 (23)	0.24
ENT Involvement:						
ENT changes at diagnosis	41 (54)	31 (69)	0.13	48 (68)	23 (74)	0.64
Nose	29 (38)	20 (44)	0.57	36 (51)	16 (52)	>0.99
Throat	2 (3)	1 (2)	>0.99	9 (13)	2 (7)	0.49
Larynx	8 (11)	3 (7)	0.75	9 (13)	2 (7)	0.49
Sinus	23 (30)	24 (53)	0.02	26 (37)	15 (48)	0.28

Salivary glands	0 (0)	1 (2)	0.37	2 (3)	0 (0)	>0.99
Ear	19 (25)	13 (29)	0.67	16 (23)	11 (36)	0.22
Mouth	8 (11)	3 (7)	0.75	9 (13)	3 (10)	>0.99
Time from symptom onset to diagnosis, months, median (IQR)	3 (2-7.25)	5 (3-8)	0.11	7 (3-24)	6 (3-22)	0.79
BVASv3 at diagnosis, mean (SD)	20.09 (6.99)	19.2 (7.45)	0.51	15 (10-21)* 16 (8.22)	18 (11-23)* 18.06 (9.86)	0.38
DEI, mean (SD)	6.75 (2.32)	7.28 (2.59)	0.24	6.74 (3.02)	6.87 (3.27)	0.85
Period from diagnosis to first relapse, months, median (IQR)	24 (10-36)	20 (9.5-41)	0.74	24 (13.25-36)	22 (10.5-32.5)	0.39
Mortality, n (%)						
Yes	17 (22)	2 (4)	0.009	9 (13)	8 (26)	0.15
No	58 (76)	43 (96)		62 (87)	23 (74)	
Missing data	1 (1)	0 (0)		0 (0)	0 (0)	

RRT=renal replacement therapy, ENT=ear, nose, throat; BVASv3= Birmingham Vasculitis Activity Score version 3; DEI=disease extent index, IQR=interquartile range, SD=standard deviation.